Adrenocortical carcinoma in the face of Li-Fraumeni syndrome - a case report Case report

Main Article Content

Tomasz Maroszczuk
Zuzanna Smuniewska
Jan Kapała
Krystian Golon


Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. ACCs are caused by a cumulation of sporadic mutations, however, some inherited mutations may predispose to ACC. This paper presents a case of a 12-years-old child diagnosed with TP53 mutation, preceded by ACC diagnosis.


Download data is not yet available.


Metrics Loading ...

Article Details

How to Cite
Maroszczuk T, Smuniewska Z, Kapała J, Golon K. Adrenocortical carcinoma in the face of Li-Fraumeni syndrome - a case report. OncoReview [Internet]. 2023Sep.1 [cited 2024Jul.18];13(3(51):71-4. Available from:


1. Mansmann G, Lau J, Balk E et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004; 25(2): 309-340.
2. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013; 98(12): 4551-64.
3. McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J Pediatr Surg. 2013; 48(5): 1025-31.
4. Kerkhofs TM, Verhoeven RH, Van der Zwan JM et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013; 49(11): 2579-86.
5. Gargallo P, Yáñez Y, Segura V et al. Li-Fraumeni syndrome heterogeneity. Clin Transl Oncol. 2020; 22(7): 978-88.
6. Jouinot A, Bertherat J. Diseases Predisposing to Adrenocortical Malignancy (Li-Fraumeni Syndrome, Beckwith Wiedemann Syndrome, and Carney Complex). Exp Suppl. 2019; 111: 149-69.
7. Chompret A, Brugières L, Ronsin M et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000; 82(12): 1932-7.
8. Kumamoto T, Yamazaki F, Nakano Y et al. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol. 2021; 26(12): 2161-78. [correction in: Int J Clin Oncol. 2022 Jan;27(1):262-263]
9. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009; 23(2): 273-89.
10. Else T, Kim AC, Sabolch A et al. Adrenocortical carcinoma. Endocr Rev. 2014; 35(2): 282-326.
11. Fassnacht M, Libé R, Kroiss M et al. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011; 7(6): 323-35.
12. Ishikura K, Takamura T, Takeshita Y et al. Cushing’s syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma. BMJ Case Rep. 2010; 2010: bcr07.2009.2100.
13. Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015; 3: 45.
14.Hubertus J, Boxberger N, Redlich A et al. Surgical aspects in the treatment of adrenocortical carcinomas in children: data of the GPOH-MET 97 trial. Klin Padiatr. 2012; 224(3): 143-7.
15. Redlich A, Boxberger N, Strugala D et al. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial. Klin Padiatr. 2012; 224(6): 366-71.